| Lack of activity of recombinant HIF prolyl hydroxylases (PHDs) on reported non-HIF substrates ME Cockman, K Lippl, YM Tian, HB Pegg, WD Figg, MI Abboud, R Heilig, ... Elife 8, e46490, 2019 | 83 | 2019 |
| Structural basis of prolyl hydroxylase domain inhibition by molidustat WD Figg Jr, MA McDonough, R Chowdhury, Y Nakashima, Z Zhang, ... ChemMedChem 16 (13), 2082-2088, 2021 | 27 | 2021 |
| Aromatase inhibitor plus ovarian suppression as adjuvant therapy in premenopausal women with breast cancer WD Figg, K Cook, R Clarke Cancer biology & therapy 15 (12), 1586-1587, 2014 | 27 | 2014 |
| Structure‐Activity Relationship and Crystallographic Studies on 4‐Hydroxypyrimidine HIF Prolyl Hydroxylase Domain Inhibitors JP Holt‐Martyn, R Chowdhury, A Tumber, TL Yeh, MI Abboud, K Lippl, ... ChemMedChem 15 (3), 270-273, 2020 | 25 | 2020 |
| Monitor tumor burden with circulating tumor DNA WD Figg II, J Reid Cancer biology & therapy 14 (8), 697-698, 2013 | 23 | 2013 |
| Multi-institutional Study of Outcomes After Pediatric Heart Transplantation: Candidate Gene Polymorphism Analysis of ABCC2 GJ Burckart, WD Figg, MM Brooks, DJ Green, SM Troutman, R Ferrell, ... The Journal of Pediatric Pharmacology and Therapeutics 19 (1), 16-24, 2014 | 22 | 2014 |
| Cabazitaxel: filling one of the gaps in the treatment of prostate cancer WD Figg, WD Figg, II Cancer Biology & Therapy 10 (12), 1233-1234, 2010 | 17 | 2010 |
| Detectible mosaic truncating PPM1D mutations, age and breast cancer risk MJ Machiela, TA Myers, CJ Lyons, R Koster, WD Figg Jr, LM Colli, ... Journal of human genetics 64 (6), 545-550, 2019 | 10 | 2019 |
| Studies on spiro [4.5] decanone prolyl hydroxylase domain inhibitors JP Holt-Martyn, A Tumber, MZ Rahman, K Lippl, W Figg, MA McDonough, ... MedChemComm 10 (4), 500-504, 2019 | 9 | 2019 |
| How do you want your steak prepared? The impact of meat consumption and preparation on prostate cancer WD Figg Cancer Biology & Therapy 13 (12), 1141-1142, 2012 | 8 | 2012 |
| Association Between Thiopurine S-Methyltransferase (TPMT) Genetic Variants and Infection in Pediatric Heart Transplant Recipients Treated With Azathioprine: A … DJ Green, SQ Duong, GJ Burckart, T Sissung, DK Price, WD Figg Jr, ... The Journal of Pediatric Pharmacology and Therapeutics 23 (2), 106-110, 2018 | 4 | 2018 |
| Structural basis for binding of the renal carcinoma target hypoxia‐inducible factor 2α to prolyl hydroxylase domain 2 WD Figg Jr, G Fiorini, R Chowdhury, Y Nakashima, A Tumber, ... Proteins: Structure, Function, and Bioinformatics 91 (11), 1510-1524, 2023 | 3 | 2023 |
| Structure-guided optimisation of N-hydroxythiazole-derived inhibitors of factor inhibiting hypoxia-inducible factor-α TP Corner, RZR Teo, Y Wu, E Salah, Y Nakashima, G Fiorini, A Tumber, ... Chemical Science 14 (43), 12098-12120, 2023 | 3 | 2023 |
| Enzalutamide for treatment of CRPC: Rationale for sequencing and potential clinical biomarker for resistance SE Lochrin, WD Figg, SP Finn Cancer Biology & Therapy 16 (2), 201-203, 2015 | 1 | 2015 |
| Structural and mechanistic studies on PHD2 and the discovery of potential inhibitors WD Figg Jr, CJ Schofield University of Oxford, 2022 | | 2022 |
| HIF-prolyl-hydroxylase 2 clinical inhibitor complex structure and XChem fragment-based screen obtained with succinate co-product used as a crystallisation tool WD Figg Jr, MA McDonough, Y Nakashima, R Chowdhury, CJ Schofield Acta Crystallographica Section A: Foundations and Advances 77, C1193-C1193, 2021 | | 2021 |
Michael McDonoughAtomic Resolution Consulting AB在 atomic-resolution.com 的电子邮件经过验证
